Clay Siegall is currently the president, chairman of the boards of directors and CEO of Seattle Genetics, a company he co-founded in 1998. He has for a long time dedicated his time to come up with a better cure for cancer. He is happy that he is making it happen for cancer patients. In an interview with Ideamensch, Siegall explains that his desire to pursue the cure cancer was born after watching his father live and succumb to it when he was 24. Living with a cancerous patient made him realize there was more to be done in medicine especially in oncology.
Siegall is a graduate of the University of Maryland where he earned a B.S in zoology and a doctorate in genetics from George Washington University. After studied he joined the Bristol-Myers Squibb Pharmaceutical Research Institute where he worked for six years since 1991. Besides, he has also worked with the National Cancer Institute. When working Bristol-Myers, he moved Seattle where he learned what it takes to run a company. That is how Seattle Genetics came to be.
Over the last three decades, clay has been working to provide a better option for cancer patients. He loves doing it better each day through rigorous research. The company has in the process of developing an anti-body conjugate that will help destroy cancerous cell before they multiply and affect other parts of the body. Seattle Genetics has collaborated with pharmaceutical companies, like Takeda Pharmaceutical Company, as it strives to make life better for cancer patients. Dr. Clay has managed to propel the company’s capital to the tunes of $1.2 billion.
Clay Siegall has urged the young generation especially those planning to engage in entrepreneurship that they should never stop learning. He feels there is the need for them to interact with professionals and experts in the various field. Clays also claim that collaborating other ventures in the industry has made his company a success. It creates an opportunity for innovation. Apart from a being a doctor, clay is also an author of many publications and also holds 15 patents.